Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKB | Q96GD4 | 4/20 | 0.72 |
| ▸ | EGFR | P00533 | 3/20 | 0.72 |
| ▸ | KDR | P35968 | 3/20 | 0.72 |
| ▸ | IGF1R | P08069 | 1/20 | 0.72 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.72 |
| ▸ | SRC | P12931 | 1/20 | 0.72 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.72 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.72 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.72 |
| ▸ | CDK2 | P24941 | 1/20 | 0.72 |
| ▸ | CSK | P41240 | 1/20 | 0.72 |
| ▸ | JAK3 | P52333 | 1/20 | 0.72 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.72 |
| ▸ | AURKA | O14965 | 17/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5045588 | 0.93 | AURKB (0.83) | AURKBEGFRKDRIGF1RFGFR1 | |
| SCHEMBL5041518 | 0.92 | AURKB (0.78) | AURKBEGFRKDRIGF1RFGFR1 | |
| SCHEMBL5045094 | 0.91 | EGFR (0.66) | AURKBEGFRKDRIGF1RFGFR1 | |
| SCHEMBL5045084 | 0.90 | AURKB (0.68) | AURKBEGFRKDRIGF1RFGFR1 | |
| SCHEMBL3885234 | 0.90 | AURKB (0.78) | AURKBEGFRKDRIGF1RFGFR1 | |
| SCHEMBL5045074 | 0.89 | AURKB (0.69) | AURKBEGFRKDRIGF1RFGFR1 | |
| SCHEMBL5045980 | 0.88 | AURKB (0.84) | AURKBEGFRKDRIGF1RFGFR1 | |
| SCHEMBL3883326 | 0.87 | AURKA (0.74) | AURKBEGFRKDRIGF1RFGFR1 | |
| SCHEMBL3891604 | 0.86 | AURKB (0.72) | AURKBEGFRKDRIGF1RFGFR1 | |
| SCHEMBL3885729 | 0.86 | AURKB (0.79) | AURKBEGFRKDRIGF1RFGFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7407946-B2 | Quinazoline compounds | ASTRAZENECA AB (SE) | 2008-08-05 | — | — | US | claimed |
| US-20060058523-A1 | Quinazoline compounds | ASTRAZENECA AB (SE) | 2006-03-16 | — | — | US | claimed |
| CN-101437577-A | Combination therapy for diseases involving angiogenesis | BAUSCH & LOMB (US) | 2009-05-20 | — | — | CN | disclosed |
| EP-2012878-A2 | COMBINATION THERAPY FOR DISEASES INVOLVING ANGIOGENESIS | Bausch & Lomb Incorporated (US) | 2009-01-14 | — | — | EP | disclosed |
| US-7407946-B2 | Quinazoline compounds | ASTRAZENECA AB (SE) | 2008-08-05 | — | — | US | disclosed |
| WO-2007130842-A2 | COMBINATION THERAPY FOR DISEASES INVOLVING ANGIOGENESIS | BAUSCH & LOMB INCORPORATED (US) | 2007-11-15 | — | — | WO | disclosed |
| US-20070258976-A1 | Combination Therapy for Diseases Involving Angiogenesis | BAUSCH & LOMB INCORPORATED | 2007-11-08 | — | — | US | disclosed |
| US-20060058523-A1 | Quinazoline compounds | ASTRAZENECA AB (SE) | 2006-03-16 | — | — | US | disclosed |
| EP-1575946-A1 | QUINAZOLINE COMPOUNDS | AstraZeneca AB (SE) | 2005-09-21 | — | — | EP | disclosed |
| WO-2004058752-A1 | QUINAZOLINE COMPOUNDS | ASTRAZENECA AB (SE) | 2004-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060058523-A1 | Quinazoline compounds | NDUFS5, ABL1, NDUFS7 | AURKB 735/4885EGFR 2379/4885KDR 2844/4885 |
| US-20070258976-A1 | Combination Therapy for Diseases Involving Angiogenesis | VEGFA, FLT4, TEK | AURKB 3406/4885EGFR 86/4885KDR 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.